08:00 , Dec 24, 2012 |  BC Week In Review  |  Financial News

Regado Biosciences completes venture financing

Regado Biosciences Inc. , Basking Ridge, N.J.   Business: Cardiovascular   Date completed: 12/19/12   Type: Venture financing   Raised: $51 million   Investors: Rusnano; Baxter Ventures; Edmond de Rothschild Investment Partners; Domain Associates; Quaker...
01:32 , Dec 20, 2012 |  BC Extra  |  Financial News

Regado raises $51 million in E round

Regado Biosciences Inc. (Basking Ridge, N.J.) raised $51 million in a series E round led by new investor Rusnano. New investor Baxter Ventures joined existing investors Edmond de Rothschild; Domain Associates; Quaker Partners; Aurora Funds;...
08:00 , Jan 31, 2011 |  BioCentury  |  Finance

Venture tracks

Jay Cecil was promoted to managing director from principal at Caxton Advantage Life Sciences Fund . Caxton Associates, of which Caxton Advantage is an affiliate, has over $10 billion under management....
07:00 , Aug 9, 2010 |  BC Week In Review  |  Financial News

Gemin X completes venture financing

Gemin X Pharmaceuticals Inc. , Malvern, Pa.   Business: Cancer   Date completed: 8/4/10   Type: Venture financing   Raised: $8 million   Investors: Caxton Advantage Life Sciences Fund; Sanderling; existing investors   Note: The...
07:00 , Jul 5, 2010 |  BC Week In Review  |  Financial News

Sunesis completes private placement

Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS), South San Francisco, Calif.   Business: Cancer   Date completed: 6/30/10   Type: Private placement   Raised: $28.5 million   Shares: 103.6 million   Price: $0.28   Shares after offering: 221.2...
23:47 , Jun 30, 2010 |  BC Extra  |  Financial News

Sunesis raises $28.5 million

Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) said late Wednesday that it raised $28.5 million through the sale of 103.6 million shares at $0.28 in the third and final tranche of a March 2009 offering, bringing the total...
07:00 , Apr 26, 2010 |  BC Week In Review  |  Financial News

Gemin X completes venture financing

Gemin X Pharmaceuticals Inc. , Malvern, Pa.   Business: Cancer   Date completed: 4/20/10   Type: Venture financing   Raised: $16 million   Investors: Caxton Advantage Life Sciences Fund; Sanderling   Note: Current investors have...
07:00 , Apr 26, 2010 |  BioCentury  |  Finance

X marks the spot

Investors in oncology play Gemin X Pharmaceuticals Inc. are hoping last week's $16 million series D round, with an optional additional $4 million, will be enough to get the company through Phase IIb data. Existing...
00:29 , Apr 21, 2010 |  BC Extra  |  Financial News

Gemin X raises $16 million

Gemin X Pharmaceuticals Inc. (Malvern, Pa.) raised $16 million in a series D round co-led by existing investors Caxton Advantage Life Sciences Fund and Sanderling Venture Partners. Gemin X's obatoclax is in Phase IIb testing...
07:00 , Apr 5, 2010 |  BioCentury  |  Finance

2Q Financial Markets Preview: Wanted Dry Powder

Biotech run-ups have historically cooled after 25-30% gains. Thus the question going into the second quarter is whether there's momentum to keep going, or whether the sector will take a breather. The historical numbers are...